Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1α (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010
- 30 June 1998
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 34 (7), 1023-1029
- https://doi.org/10.1016/s0959-8049(97)10141-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5Nature, 1996
- BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical propertiesBlood, 1995
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995
- Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8.The Journal of Experimental Medicine, 1993
- Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha.The Journal of Experimental Medicine, 1993
- Fever and feeding: Differential actions of macrophage inflammatory protein-1 (MIP-1), MIP-1? and MIP-1? on rat hypothalamusNeurochemical Research, 1993
- Interferon-gamma (IFN-γ) and macrophage inflammatory proteins (MIP)-1 and -2 are involved in the regulation of the T cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteriaClinical and Experimental Immunology, 1992
- Biological and structural properties of MIP-1$alpha; expressed in yeastCytokine, 1992
- Macrophage Inflammatory Protein-1: a Prostaglandin-Independent Endogenous PyrogenScience, 1989
- Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties.The Journal of Experimental Medicine, 1988